<DOC>
	<DOCNO>NCT00686075</DOCNO>
	<brief_summary>Primary objective study describe safety tolerability multiple dose MEDI-534 child 6 less ( &lt; ) 24 month age infants 2 month age .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Immunogenicity Vaccine-like Viral Shedding MEDI-534 , Against Respiratory Syncytial Virus ( RSV ) Parainfluenza Virus Type 3 ( PIV3 ) , Healthy 6 &lt; 24 Month-old Children 2 Month-old Infants</brief_title>
	<detailed_description>This Phase 1/2a , randomize , double-blind , placebo-controlled , dose-escalation , multicenter study evaluate safety tolerability multiple dose MEDI-534 10^5 10^6 median tissue culture infectious dose ( TCID50 ) RSV PIV3 seronegative child 6 &lt; 24 month age dosages 10^4 , 10^5 10^6 TCID50 unscreened infant 2 month age .</detailed_description>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<criteria>Male female whose age day randomization fall within one two age group : 6 less ( &lt; ) 24 month ( [ &gt; ] 6 month age yet reach 2nd year birthday ) , Cohorts 1 2 2 month ( +/ 4 week ) , Cohorts 3 , 4 , 5 Cohorts 1 2 : Subject seronegative Respiratory Syncytial Virus ( RSV ) human Parainfluenza Virus Type 3 ( hPIV3 ) Screening Subject whose gestational age great equal ( &gt; = ) 36 week Subject general good health normal growth ( , body weight great ( &gt; ) third percentile per world health organization [ WHO ] simplify weightperage field table Subject 's legal representative available telephone Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization ( applicable ) obtain subject 's legal representative Subject 's legal representative able understand comply requirement protocol judge investigator Subject available complete followup period 1year receipt first dose study vaccine Subject 's legal representative must willing able bring subject study site evaluation respiratory illness accordance protocol . Any fever ( &gt; =100.4 degree Fahrenheit [ &gt; =38.0 degrees Celsius ] , regardless route ) low respiratory illness within 7 day prior randomization Moderate severe nasal congestion investigator 's opinion could interfere intranasal delivery study vaccine Acute illness ( define presence moderate severe sign symptom ) time randomization Any drug therapy ( chronic ) within 7 day prior randomization expect receipt protocolspecified blood collection 28 day study vaccine dosing , except infrequent use overthecounter medication systemic treatment common childhood symptom ( , pain reliever , decongestant cough suppressant ) permit accord judgment investigator Any current expect receipt immunosuppressive agent include steroid ( &gt; =2 milligram per kilogram [ mg/kg ] per day prednisone equivalent , &gt; =20 milligram per day [ mg/day ] subject weigh &gt; 10 kilogram [ kg ] , give daily alternate day &gt; =14 day ) ; child category receive study vaccine immunosuppressive agent include corticosteroid therapy discontinue &gt; =30 day ; use topical steroid permit accord judgment investigator History receipt blood transfusion expect receipt protocolspecified blood collection 28 day final study dose History receipt immunoglobulin product expect receipt protocolspecified blood collection 28 day final study dose Receipt investigational drug within 60 day prior randomization expect receipt 180 day final study dose Receipt live virus vaccine ( exclude oral polio vaccine rotavirus vaccine ) within 28 day prior randomization expect receipt within 28day window around study vaccine dose Receipt inactivate ( , nonlive ) vaccine oral polio vaccine rotavirus vaccine within 14 day prior randomization expect receipt within 14day window around study vaccine dose Known suspect immunodeficiency , include human immunodeficiency virus ( HIV ) infection Expected living home enrol classroom day care infant &lt; 6 month within 28 day dose Living household another child concurrently enrol study live viral vaccine ( include study ) Expected contact pregnant caregiver within 28 day dose A household contact immunocompromised ; subject also avoid close contact immunocompromised individual least 28 day study vaccine dose Expected household contact within 28 day dose health care provider immunocompromised subject day care provider infant age 6 month History allergic reaction component study vaccine Previous medical history , evidence , intercurrent chronic illness , opinion investigator , may compromise safety subject Known suspect active chronic hepatitis infection History medical diagnosis asthma , reactive airway disease , wheeze require medication , cystic fibrosis , bronchopulmonary dysplasia , chronic pulmonary disease , medically confirm apnea , hospitalization respiratory illness mechanical ventilation respiratory illness ( excludes elective mechanical ventilation surgery subject Cohorts 1 2 ) Family member household contact employee research center otherwise involved conduct study Any condition , opinion investigator , might interfere study vaccine evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Respiratory Syncytial Virus ( RSV )</keyword>
	<keyword>Parainfluenza Virus Type 3 ( PIV3 )</keyword>
	<keyword>MEDI-534</keyword>
</DOC>